InMed Pharmaceuticals (NASDAQ: INM), a is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s...
InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, will be featured in this week’s Emerging Growth...
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pipeline...
InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, is reporting on its financial and business results...
Reported positive preclinical data in both its Alzheimer's and dry AMD programsClosed Fiscal Q3 with cash position of US$7.9 millionVancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - InMed...
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD,...
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization...
InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical...
Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease...
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data...